世界の腎臓癌治療薬市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Kidney Cancer Medicine Market Size, Status and Forecast 2021-2027

• レポートコード：QFJ1-5820 • 出版社/出版日：QYResearch / 2021年6月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、124ページ • 納品方法：Eメール（納期：3日） • 産業分類：医薬品

• 販売価格（消費税別）

Single User	￥577,200 (USD3,900)	▷ お問い合わせ
Multi User	￥865,800 (USD5,850)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

QYResearch社発行の本調査レポートでは、腎臓癌治療薬の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（モノクローナル抗体、mTOR阻害剤、キナーゼ阻害剤、その他）、用途別市場規模（腎細胞癌（RCC）、移行上皮癌（TCC））、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、企業情報などをまとめております。 ・市場概要 ・腎臓癌治療薬の市場動向 ・企業の競争状況、市場シェア ・腎臓癌治療薬の種類別市場規模と予測2016-2027（モノクローナル抗体、mTOR阻害剤、キナーゼ阻害剤、その他） ・腎臓癌治療薬の用途別市場規模と予測2016-2027（腎細胞癌（RCC）、移行上皮癌（TCC）） ・腎臓癌治療薬の北米市場規模2016-2027（アメリカ、カナダ） ・腎臓癌治療薬の欧州市場規模2016-2027（ドイツ、フランス、イギリス等） ・腎臓癌治療薬のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・腎臓癌治療薬の中南米市場規模2016-2027（メキシコ、ブラジル） ・腎臓癌治療薬の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Pfizer、Bristol-Myers Squibb、Roche、GSK、Novartis、Bayer、Merck & Co.、Exelixis、Takeda、Eisai、CTTQ、AVEO Oncology、Everest Pharm、Cipla、NATCO、Beacon Pharma、SAMARTH） ・結論

Kidney cancer — also called renal cancer — is a disease in which kidney cells become malignant (cancerous) and grow out of control, forming a tumor. Almost all kidney cancers first appear in the lining of tiny tubes (tubules) in the kidney. This type of kidney cancer is called renal cell carcinoma.
Renal cell carcinoma (RCC) is a common malignant tumor worldwide, referred to as kidney cancer. According to the World Health Organization, the global incidence of kidney cancer accounts for 2% to 3% of systemic tumors. Among malignant tumors of the urinary system, its incidence is second only to bladder cancer, and it is increasing year by year. In recent years, targeted therapy and precision therapy have become standard treatments for kidney cancer.

Market Analysis and Insights: Global Kidney Cancer Medicine Market
The global Kidney Cancer Medicine market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Kidney Cancer Medicine market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Kidney Cancer Medicine market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Kidney Cancer Medicine market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Kidney Cancer Medicine market.

Global Kidney Cancer Medicine Scope and Market Size
Kidney Cancer Medicine market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Kidney Cancer Medicine market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Monoclonal Antibody
mTOR Inhibitors
Kinase Inhibitors
Other

Segment by Application
Renal Cell Carcinoma (RCC)
Transitional Cell Carcinoma (TCC)

By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Pfizer
Bristol-Myers Squibb
Roche
GSK
Novartis
Bayer
Merck & Co.
Exelixis
Takeda
Eisai
CTTQ
AVEO Oncology
Everest Pharm
Cipla
NATCO
Beacon Pharma
SAMARTH

レポート目次

---

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Kidney Cancer Medicine Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Monoclonal Antibody
1.2.3 mTOR Inhibitors
1.2.4 Kinase Inhibitors
1.2.5 Other
1.3 Market by Application
1.3.1 Global Kidney Cancer Medicine Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Renal Cell Carcinoma (RCC)
1.3.3 Transitional Cell Carcinoma (TCC)
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Kidney Cancer Medicine Market Perspective (2016-2027)
2.2 Kidney Cancer Medicine Growth Trends by Regions
2.2.1 Kidney Cancer Medicine Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Kidney Cancer Medicine Historic Market Share by Regions (2016-2021)
2.2.3 Kidney Cancer Medicine Forecasted Market Size by Regions (2022-2027)
2.3 Kidney Cancer Medicine Industry Dynamic
2.3.1 Kidney Cancer Medicine Market Trends
2.3.2 Kidney Cancer Medicine Market Drivers
2.3.3 Kidney Cancer Medicine Market Challenges
2.3.4 Kidney Cancer Medicine Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Kidney Cancer Medicine Players by Revenue
3.1.1 Global Top Kidney Cancer Medicine Players by Revenue (2016-2021)
3.1.2 Global Kidney Cancer Medicine Revenue Market Share by Players (2016-2021)
3.2 Global Kidney Cancer Medicine Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Kidney Cancer Medicine Revenue
3.4 Global Kidney Cancer Medicine Market Concentration Ratio
3.4.1 Global Kidney Cancer Medicine Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Kidney Cancer Medicine Revenue in 2020
3.5 Kidney Cancer Medicine Key Players Head office and Area Served
3.6 Key Players Kidney Cancer Medicine Product Solution and Service
3.7 Date of Enter into Kidney Cancer Medicine Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Kidney Cancer Medicine Breakdown Data by Type
4.1 Global Kidney Cancer Medicine Historic Market Size by Type (2016-2021)
4.2 Global Kidney Cancer Medicine Forecasted Market Size by Type (2022-2027)

5 Kidney Cancer Medicine Breakdown Data by Application
5.1 Global Kidney Cancer Medicine Historic Market Size by Application (2016-2021)
5.2 Global Kidney Cancer Medicine Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Kidney Cancer Medicine Market Size (2016-2027)
6.2 North America Kidney Cancer Medicine Market Size by Type
6.2.1 North America Kidney Cancer Medicine Market Size by Type (2016-2021)
6.2.2 North America Kidney Cancer Medicine Market Size by Type (2022-2027)
6.2.3 North America Kidney Cancer Medicine Market Size by Type (2016-2027)
6.3 North America Kidney Cancer Medicine Market Size by Application
6.3.1 North America Kidney Cancer Medicine Market Size by Application (2016-2021)
6.3.2 North America Kidney Cancer Medicine Market Size by Application (2022-2027)
6.3.3 North America Kidney Cancer Medicine Market Size by Application (2016-2027)
6.4 North America Kidney Cancer Medicine Market Size by Country
6.4.1 North America Kidney Cancer Medicine Market Size by Country (2016-2021)
6.4.2 North America Kidney Cancer Medicine Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada

7 Europe
7.1 Europe Kidney Cancer Medicine Market Size (2016-2027)
7.2 Europe Kidney Cancer Medicine Market Size by Type
7.2.1 Europe Kidney Cancer Medicine Market Size by Type (2016-2021)
7.2.2 Europe Kidney Cancer Medicine Market Size by Type (2022-2027)
7.2.3 Europe Kidney Cancer Medicine Market Size by Type (2016-2027)
7.3 Europe Kidney Cancer Medicine Market Size by Application
7.3.1 Europe Kidney Cancer Medicine Market Size by Application (2016-2021)
7.3.2 Europe Kidney Cancer Medicine Market Size by Application (2022-2027)
7.3.3 Europe Kidney Cancer Medicine Market Size by Application (2016-2027)
7.4 Europe Kidney Cancer Medicine Market Size by Country
7.4.1 Europe Kidney Cancer Medicine Market Size by Country (2016-2021)
7.4.2 Europe Kidney Cancer Medicine Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Kidney Cancer Medicine Market Size (2016-2027)
8.2 Asia-Pacific Kidney Cancer Medicine Market Size by Type
8.2.1 Asia-Pacific Kidney Cancer Medicine Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Kidney Cancer Medicine Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Kidney Cancer Medicine Market Size by Type (2016-2027)
8.3 Asia-Pacific Kidney Cancer Medicine Market Size by Application
8.3.1 Asia-Pacific Kidney Cancer Medicine Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Kidney Cancer Medicine Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Kidney Cancer Medicine Market Size by Application (2016-2027)
8.4 Asia-Pacific Kidney Cancer Medicine Market Size by Region
8.4.1 Asia-Pacific Kidney Cancer Medicine Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Kidney Cancer Medicine Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Kidney Cancer Medicine Market Size (2016-2027)
9.2 Latin America Kidney Cancer Medicine Market Size by Type
9.2.1 Latin America Kidney Cancer Medicine Market Size by Type (2016-2021)
9.2.2 Latin America Kidney Cancer Medicine Market Size by Type (2022-2027)
9.2.3 Latin America Kidney Cancer Medicine Market Size by Type (2016-2027)
9.3 Latin America Kidney Cancer Medicine Market Size by Application
9.3.1 Latin America Kidney Cancer Medicine Market Size by Application (2016-2021)
9.3.2 Latin America Kidney Cancer Medicine Market Size by Application (2022-2027)
9.3.3 Latin America Kidney Cancer Medicine Market Size by Application (2016-2027)
9.4 Latin America Kidney Cancer Medicine Market Size by Country
9.4.1 Latin America Kidney Cancer Medicine Market Size by Country (2016-2021)
9.4.2 Latin America Kidney Cancer Medicine Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Kidney Cancer Medicine Market Size (2016-2027)
10.2 Middle East & Africa Kidney Cancer Medicine Market Size by Type
10.2.1 Middle East & Africa Kidney Cancer Medicine Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Kidney Cancer Medicine Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Kidney Cancer Medicine Market Size by Type (2016-2027)
10.3 Middle East & Africa Kidney Cancer Medicine Market Size by Application
10.3.1 Middle East & Africa Kidney Cancer Medicine Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Kidney Cancer Medicine Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Kidney Cancer Medicine Market Size by Application (2016-2027)
10.4 Middle East & Africa Kidney Cancer Medicine Market Size by Country
10.4.1 Middle East & Africa Kidney Cancer Medicine Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Kidney Cancer Medicine Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Pfizer
11.1.1 Pfizer Company Details
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Kidney Cancer Medicine Introduction
11.1.4 Pfizer Revenue in Kidney Cancer Medicine Business (2016-2021)
11.1.5 Pfizer Recent Development
11.2 Bristol-Myers Squibb
11.2.1 Bristol-Myers Squibb Company Details
11.2.2 Bristol-Myers Squibb Business Overview
11.2.3 Bristol-Myers Squibb Kidney Cancer Medicine Introduction
11.2.4 Bristol-Myers Squibb Revenue in Kidney Cancer Medicine Business (2016-2021)
11.2.5 Bristol-Myers Squibb Recent Development
11.3 Roche
11.3.1 Roche Company Details
11.3.2 Roche Business Overview
11.3.3 Roche Kidney Cancer Medicine Introduction
11.3.4 Roche Revenue in Kidney Cancer Medicine Business (2016-2021)
11.3.5 Roche Recent Development
11.4 GSK
11.4.1 GSK Company Details
11.4.2 GSK Business Overview
11.4.3 GSK Kidney Cancer Medicine Introduction
11.4.4 GSK Revenue in Kidney Cancer Medicine Business (2016-2021)
11.4.5 GSK Recent Development
11.5 Novartis
11.5.1 Novartis Company Details
11.5.2 Novartis Business Overview
11.5.3 Novartis Kidney Cancer Medicine Introduction
11.5.4 Novartis Revenue in Kidney Cancer Medicine Business (2016-2021)
11.5.5 Novartis Recent Development
11.6 Bayer
11.6.1 Bayer Company Details
11.6.2 Bayer Business Overview
11.6.3 Bayer Kidney Cancer Medicine Introduction
11.6.4 Bayer Revenue in Kidney Cancer Medicine Business (2016-2021)
11.6.5 Bayer Recent Development
11.7 Merck & Co.
11.7.1 Merck & Co. Company Details
11.7.2 Merck & Co. Business Overview
11.7.3 Merck & Co. Kidney Cancer Medicine Introduction
11.7.4 Merck & Co. Revenue in Kidney Cancer Medicine Business (2016-2021)
11.7.5 Merck & Co. Recent Development
11.8 Exelixis
11.8.1 Exelixis Company Details
11.8.2 Exelixis Business Overview
11.8.3 Exelixis Kidney Cancer Medicine Introduction
11.8.4 Exelixis Revenue in Kidney Cancer Medicine Business (2016-2021)
11.8.5 Exelixis Recent Development
11.9 Takeda
11.9.1 Takeda Company Details
11.9.2 Takeda Business Overview
11.9.3 Takeda Kidney Cancer Medicine Introduction
11.9.4 Takeda Revenue in Kidney Cancer Medicine Business (2016-2021)
11.9.5 Takeda Recent Development
11.10 Eisai
11.10.1 Eisai Company Details
11.10.2 Eisai Business Overview
11.10.3 Eisai Kidney Cancer Medicine Introduction
11.10.4 Eisai Revenue in Kidney Cancer Medicine Business (2016-2021)
11.10.5 Eisai Recent Development
11.11 CTTQ
11.11.1 CTTQ Company Details
11.11.2 CTTQ Business Overview
11.11.3 CTTQ Kidney Cancer Medicine Introduction
11.11.4 CTTQ Revenue in Kidney Cancer Medicine Business (2016-2021)
11.11.5 CTTQ Recent Development
11.12 AVEO Oncology
11.12.1 AVEO Oncology Company Details
11.12.2 AVEO Oncology Business Overview
11.12.3 AVEO Oncology Kidney Cancer Medicine Introduction
11.12.4 AVEO Oncology Revenue in Kidney Cancer Medicine Business (2016-2021)
11.12.5 AVEO Oncology Recent Development
11.13 Everest Pharm
11.13.1 Everest Pharm Company Details
11.13.2 Everest Pharm Business Overview
11.13.3 Everest Pharm Kidney Cancer Medicine Introduction
11.13.4 Everest Pharm Revenue in Kidney Cancer Medicine Business (2016-2021)
11.13.5 Everest Pharm Recent Development
11.14 Cipla
11.14.1 Cipla Company Details
11.14.2 Cipla Business Overview
11.14.3 Cipla Kidney Cancer Medicine Introduction
11.14.4 Cipla Revenue in Kidney Cancer Medicine Business (2016-2021)
11.14.5 Cipla Recent Development
11.15 NATCO
11.15.1 NATCO Company Details
11.15.2 NATCO Business Overview
11.15.3 NATCO Kidney Cancer Medicine Introduction
11.15.4 NATCO Revenue in Kidney Cancer Medicine Business (2016-2021)
11.15.5 NATCO Recent Development
11.16 Beacon Pharma
11.16.1 Beacon Pharma Company Details
11.16.2 Beacon Pharma Business Overview
11.16.3 Beacon Pharma Kidney Cancer Medicine Introduction
11.16.4 Beacon Pharma Revenue in Kidney Cancer Medicine Business (2016-2021)
11.16.5 Beacon Pharma Recent Development
11.17 SAMARTH
11.17.1 SAMARTH Company Details
11.17.2 SAMARTH Business Overview
11.17.3 SAMARTH Kidney Cancer Medicine Introduction
11.17.4 SAMARTH Revenue in Kidney Cancer Medicine Business (2016-2021)
11.17.5 SAMARTH Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Kidney Cancer Medicine Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Monoclonal Antibody
Table 3. Key Players of mTOR Inhibitors
Table 4. Key Players of Kinase Inhibitors
Table 5. Key Players of Other
Table 6. Global Kidney Cancer Medicine Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 7. Global Kidney Cancer Medicine Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 8. Global Kidney Cancer Medicine Market Size by Regions (2016-2021) & (US$ Million)
Table 9. Global Kidney Cancer Medicine Market Share by Regions (2016-2021)
Table 10. Global Kidney Cancer Medicine Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 11. Global Kidney Cancer Medicine Market Share by Regions (2022-2027)
Table 12. Kidney Cancer Medicine Market Trends
Table 13. Kidney Cancer Medicine Market Drivers
Table 14. Kidney Cancer Medicine Market Challenges
Table 15. Kidney Cancer Medicine Market Restraints
Table 16. Global Kidney Cancer Medicine Revenue by Players (2016-2021) & (US$ Million)
Table 17. Global Kidney Cancer Medicine Market Share by Players (2016-2021)
Table 18. Global Top Kidney Cancer Medicine Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Kidney Cancer Medicine as of 2020)
Table 19. Ranking of Global Top Kidney Cancer Medicine Companies by Revenue (US$ Million) in 2020
Table 20. Global 5 Largest Players Market Share by Kidney Cancer Medicine Revenue (CR5 and HHI) & (2016-2021)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Kidney Cancer Medicine Product Solution and Service
Table 23. Date of Enter into Kidney Cancer Medicine Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Kidney Cancer Medicine Market Size by Type (2016-2021) (US$ Million)
Table 26. Global Kidney Cancer Medicine Revenue Market Share by Type (2016-2021)
Table 27. Global Kidney Cancer Medicine Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 28. Global Kidney Cancer Medicine Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 29. Global Kidney Cancer Medicine Market Size Share by Application (2016-2021) & (US$ Million)
Table 30. Global Kidney Cancer Medicine Revenue Market Share by Application (2016-2021)
Table 31. Global Kidney Cancer Medicine Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 32. Global Kidney Cancer Medicine Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 33. North America Kidney Cancer Medicine Market Size by Type (2016-2021) (US$ Million)
Table 34. North America Kidney Cancer Medicine Market Size by Type (2022-2027) & (US$ Million)
Table 35. North America Kidney Cancer Medicine Market Size by Application (2016-2021) (US$ Million)
Table 36. North America Kidney Cancer Medicine Market Size by Application (2022-2027) & (US$ Million)
Table 37. North America Kidney Cancer Medicine Market Size by Country (2016-2021) & (US$ Million)
Table 38. North America Kidney Cancer Medicine Market Size by Country (2022-2027) & (US$ Million)
Table 39. Europe Kidney Cancer Medicine Market Size by Type (2016-2021) (US$ Million)
Table 40. Europe Kidney Cancer Medicine Market Size by Type (2022-2027) & (US$ Million)
Table 41. Europe Kidney Cancer Medicine Market Size by Application (2016-2021) (US$ Million)
Table 42. Europe Kidney Cancer Medicine Market Size by Application (2022-2027) & (US$ Million)
Table 43. Europe Kidney Cancer Medicine Market Size by Country (2016-2021) & (US$ Million)
Table 44. Europe Kidney Cancer Medicine Market Size by Country (2022-2027) & (US$ Million)
Table 45. Asia-Pacific Kidney Cancer Medicine Market Size by Type (2016-2021) (US$ Million)
Table 46. Asia-Pacific Kidney Cancer Medicine Market Size by Type (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Kidney Cancer Medicine Market Size by Application (2016-2021) (US$ Million)
Table 48. Asia-Pacific Kidney Cancer Medicine Market Size by Application (2022-2027) & (US$ Million)
Table 49. Asia-Pacific Kidney Cancer Medicine Market Size by Region (2016-2021) & (US$ Million)
Table 50. Asia-Pacific Kidney Cancer Medicine Market Size by Region (2022-2027) & (US$ Million)
Table 51. Latin America Kidney Cancer Medicine Market Size by Type (2016-2021) (US$ Million)
Table 52. Latin America Kidney Cancer Medicine Market Size by Type (2022-2027) & (US$ Million)
Table 53. Latin America Kidney Cancer Medicine Market Size by Application (2016-2021) (US$ Million)
Table 54. Latin America Kidney Cancer Medicine Market Size by Application (2022-2027) & (US$ Million)
Table 55. Latin America Kidney Cancer Medicine Market Size by Country (2016-2021) & (US$ Million)
Table 56. Latin America Kidney Cancer Medicine Market Size by Country (2022-2027) & (US$ Million)
Table 57. Middle East & Africa Kidney Cancer Medicine Market Size by Type (2016-2021) (US$ Million)
Table 58. Middle East & Africa Kidney Cancer Medicine Market Size by Type (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Kidney Cancer Medicine Market Size by Application (2016-2021) (US$ Million)
Table 60. Middle East & Africa Kidney Cancer Medicine Market Size by Application (2022-2027) & (US$ Million)
Table 61. Middle East & Africa Kidney Cancer Medicine Market Size by Country (2016-2021) & (US$ Million)
Table 62. Middle East & Africa Kidney Cancer Medicine Market Size by Country (2022-2027) & (US$ Million)
Table 63. Pfizer Company Details
Table 64. Pfizer Business Overview
Table 65. Pfizer Kidney Cancer Medicine Product
Table 66. Pfizer Revenue in Kidney Cancer Medicine Business (2016-2021) & (US$ Million)
Table 67. Pfizer Recent Development
Table 68. Bristol-Myers Squibb Company Details
Table 69. Bristol-Myers Squibb Business Overview
Table 70. Bristol-Myers Squibb Kidney Cancer Medicine Product
Table 71. Bristol-Myers Squibb Revenue in Kidney Cancer Medicine Business (2016-2021) & (US$ Million)
Table 72. Bristol-Myers Squibb Recent Development
Table 73. Roche Company Details
Table 74. Roche Business Overview
Table 75. Roche Kidney Cancer Medicine Product
Table 76. Roche Revenue in Kidney Cancer Medicine Business (2016-2021) & (US$ Million)
Table 77. Roche Recent Development
Table 78. GSK Company Details
Table 79. GSK Business Overview
Table 80. GSK Kidney Cancer Medicine Product
Table 81. GSK Revenue in Kidney Cancer Medicine Business (2016-2021) & (US$ Million)
Table 82. GSK Recent Development
Table 83. Novartis Company Details
Table 84. Novartis Business Overview
Table 85. Novartis Kidney Cancer Medicine Product
Table 86. Novartis Revenue in Kidney Cancer Medicine Business (2016-2021) & (US$ Million)
Table 87. Novartis Recent Development
Table 88. Bayer Company Details
Table 89. Bayer Business Overview
Table 90. Bayer Kidney Cancer Medicine Product
Table 91. Bayer Revenue in Kidney Cancer Medicine Business (2016-2021) & (US$ Million)
Table 92. Bayer Recent Development
Table 93. Merck & Co. Company Details
Table 94. Merck & Co. Business Overview
Table 95. Merck & Co. Kidney Cancer Medicine Product
Table 96. Merck & Co. Revenue in Kidney Cancer Medicine Business (2016-2021) & (US$ Million)
Table 97. Merck & Co. Recent Development
Table 98. Exelixis Company Details
Table 99. Exelixis Business Overview
Table 100. Exelixis Revenue in Kidney Cancer Medicine Business (2016-2021) & (US$ Million)
Table 101. Exelixis Recent Development
Table 102. Takeda Company Details
Table 103. Takeda Business Overview
Table 104. Takeda Kidney Cancer Medicine Product
Table 105. Takeda Revenue in Kidney Cancer Medicine Business (2016-2021) & (US$ Million)
Table 106. Takeda Recent Development
Table 107. Eisai Company Details
Table 108. Eisai Business Overview
Table 109. Eisai Kidney Cancer Medicine Product
Table 110. Eisai Revenue in Kidney Cancer Medicine Business (2016-2021) & (US$ Million)
Table 111. Eisai Recent Development
Table 112. CTTQ Company Details
Table 113. CTTQ Business Overview
Table 114. CTTQ Kidney Cancer Medicine Product
Table 115. CTTQ Revenue in Kidney Cancer Medicine Business (2016-2021) & (US$ Million)
Table 116. CTTQ Recent Development
Table 117. AVEO Oncology Company Details
Table 118. AVEO Oncology Business Overview
Table 119. AVEO Oncology Kidney Cancer Medicine Product
Table 120. AVEO Oncology Revenue in Kidney Cancer Medicine Business (2016-2021) & (US$ Million)
Table 121. AVEO Oncology Recent Development
Table 122. Everest Pharm Company Details
Table 123. Everest Pharm Business Overview
Table 124. Everest Pharm Kidney Cancer Medicine Product
Table 125. Everest Pharm Revenue in Kidney Cancer Medicine Business (2016-2021) & (US$ Million)
Table 126. Everest Pharm Recent Development
Table 127. Cipla Company Details
Table 128. Cipla Business Overview
Table 129. Cipla Kidney Cancer Medicine Product
Table 130. Cipla Revenue in Kidney Cancer Medicine Business (2016-2021) & (US$ Million)
Table 131. Cipla Recent Development
Table 132. NATCO Company Details
Table 133. NATCO Business Overview
Table 134. NATCO Kidney Cancer Medicine Product
Table 135. NATCO Revenue in Kidney Cancer Medicine Business (2016-2021) & (US$ Million)
Table 136. NATCO Recent Development
Table 137. Beacon Pharma Company Details
Table 138. Beacon Pharma Business Overview
Table 139. Beacon Pharma Kidney Cancer Medicine Product
Table 140. Beacon Pharma Revenue in Kidney Cancer Medicine Business (2016-2021) & (US$ Million)
Table 141. Beacon Pharma Recent Development
Table 142. SAMARTH Company Details
Table 143. SAMARTH Business Overview
Table 144. SAMARTH Kidney Cancer Medicine Product
Table 145. SAMARTH Revenue in Kidney Cancer Medicine Business (2016-2021) & (US$ Million)
Table 146. SAMARTH Recent Development
Table 147. Research Programs/Design for This Report
Table 148. Key Data Information from Secondary Sources
Table 149. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Kidney Cancer Medicine Market Share by Type: 2020 VS 2027
Figure 2. Monoclonal Antibody Features
Figure 3. mTOR Inhibitors Features
Figure 4. Kinase Inhibitors Features
Figure 5. Other Features
Figure 6. Global Kidney Cancer Medicine Market Share by Application: 2020 VS 2027
Figure 7. Renal Cell Carcinoma (RCC) Case Studies
Figure 8. Transitional Cell Carcinoma (TCC) Case Studies
Figure 9. Kidney Cancer Medicine Report Years Considered
Figure 10. Global Kidney Cancer Medicine Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 11. Global Kidney Cancer Medicine Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 12. Global Kidney Cancer Medicine Market Share by Regions: 2020 VS 2027
Figure 13. Global Kidney Cancer Medicine Market Share by Regions (2022-2027)
Figure 14. Global Kidney Cancer Medicine Market Share by Players in 2020
Figure 15. Global Top Kidney Cancer Medicine Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Kidney Cancer Medicine as of 2020
Figure 16. The Top 10 and 5 Players Market Share by Kidney Cancer Medicine Revenue in 2020
Figure 17. Global Kidney Cancer Medicine Revenue Market Share by Type (2016-2021)
Figure 18. Global Kidney Cancer Medicine Revenue Market Share by Type (2022-2027)
Figure 19. North America Kidney Cancer Medicine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 20. North America Kidney Cancer Medicine Market Share by Type (2016-2027)
Figure 21. North America Kidney Cancer Medicine Market Share by Application (2016-2027)
Figure 22. North America Kidney Cancer Medicine Market Share by Country (2016-2027)
Figure 23. United States Kidney Cancer Medicine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 24. Canada Kidney Cancer Medicine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Europe Kidney Cancer Medicine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Europe Kidney Cancer Medicine Market Share by Type (2016-2027)
Figure 27. Europe Kidney Cancer Medicine Market Share by Application (2016-2027)
Figure 28. Europe Kidney Cancer Medicine Market Share by Country (2016-2027)
Figure 29. Germany Kidney Cancer Medicine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. France Kidney Cancer Medicine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. U.K. Kidney Cancer Medicine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. Italy Kidney Cancer Medicine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Russia Kidney Cancer Medicine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Nordic Kidney Cancer Medicine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Asia-Pacific Kidney Cancer Medicine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Asia-Pacific Kidney Cancer Medicine Market Share by Type (2016-2027)
Figure 37. Asia-Pacific Kidney Cancer Medicine Market Share by Application (2016-2027)
Figure 38. Asia-Pacific Kidney Cancer Medicine Market Share by Region (2016-2027)
Figure 39. China Kidney Cancer Medicine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. Japan Kidney Cancer Medicine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. South Korea Kidney Cancer Medicine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. Southeast Asia Kidney Cancer Medicine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. India Kidney Cancer Medicine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Australia Kidney Cancer Medicine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Latin America Kidney Cancer Medicine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Latin America Kidney Cancer Medicine Market Share by Type (2016-2027)
Figure 47. Latin America Kidney Cancer Medicine Market Share by Application (2016-2027)
Figure 48. Latin America Kidney Cancer Medicine Market Share by Country (2016-2027)
Figure 49. Mexico Kidney Cancer Medicine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Brazil Kidney Cancer Medicine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Middle East & Africa Kidney Cancer Medicine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Middle East & Africa Kidney Cancer Medicine Market Share by Type (2016-2027)
Figure 53. Middle East & Africa Kidney Cancer Medicine Market Share by Application (2016-2027)
Figure 54. Middle East & Africa Kidney Cancer Medicine Market Share by Country (2016-2027)
Figure 55. Turkey Kidney Cancer Medicine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. Saudi Arabia Kidney Cancer Medicine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. UAE Kidney Cancer Medicine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. Pfizer Revenue Growth Rate in Kidney Cancer Medicine Business (2016-2021)
Figure 59. Bristol-Myers Squibb Revenue Growth Rate in Kidney Cancer Medicine Business (2016-2021)
Figure 60. Roche Revenue Growth Rate in Kidney Cancer Medicine Business (2016-2021)
Figure 61. GSK Revenue Growth Rate in Kidney Cancer Medicine Business (2016-2021)
Figure 62. Novartis Revenue Growth Rate in Kidney Cancer Medicine Business (2016-2021)
Figure 63. Bayer Revenue Growth Rate in Kidney Cancer Medicine Business (2016-2021)
Figure 64. Merck & Co. Revenue Growth Rate in Kidney Cancer Medicine Business (2016-2021)
Figure 65. Exelixis Revenue Growth Rate in Kidney Cancer Medicine Business (2016-2021)
Figure 66. Takeda Revenue Growth Rate in Kidney Cancer Medicine Business (2016-2021)
Figure 67. Eisai Revenue Growth Rate in Kidney Cancer Medicine Business (2016-2021)
Figure 68. CTTQ Revenue Growth Rate in Kidney Cancer Medicine Business (2016-2021)
Figure 69. AVEO Oncology Revenue Growth Rate in Kidney Cancer Medicine Business (2016-2021)
Figure 70. Everest Pharm Revenue Growth Rate in Kidney Cancer Medicine Business (2016-2021)
Figure 71. Cipla Revenue Growth Rate in Kidney Cancer Medicine Business (2016-2021)
Figure 72. NATCO Revenue Growth Rate in Kidney Cancer Medicine Business (2016-2021)
Figure 73. Beacon Pharma Revenue Growth Rate in Kidney Cancer Medicine Business (2016-2021)
Figure 74. SAMARTH Revenue Growth Rate in Kidney Cancer Medicine Business (2016-2021)
Figure 75. Bottom-up and Top-down Approaches for This Report
Figure 76. Data Triangulation
Figure 77. Key Executives Interviewed

---